Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PD...
Saved in:
| Published in | Journal of experimental & clinical cancer research Vol. 43; no. 1; pp. 165 - 20 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
14.06.2024
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PDAC and the glucocorticoid (GC) budesonide, a first-line therapy to treat asthma.
We tested the effect of budesonide and the classical GCs on the morphology, proliferation, migration and invasiveness of patient-derived PDAC cells and pancreatic cancer cell lines, using 2D and 3D cultures in vitro. Furthermore, a xenograft model was used to investigate the effect of budesonide on PDAC tumor growth in vivo. Finally, we combined genome-wide transcriptome analysis with genetic and pharmacological approaches to explore the mechanisms underlying budesonide activities in the different environmental conditions.
We found that in 2D culture settings, high micromolar concentrations of budesonide reduced the mesenchymal invasive/migrating features of PDAC cells, without affecting proliferation or survival. This activity was specific and independent of the Glucocorticoid Receptor (GR). Conversely, in a more physiological 3D environment, low nanomolar concentrations of budesonide strongly reduced PDAC cell proliferation in a GR-dependent manner. Accordingly, we found that budesonide reduced PDAC tumor growth in vivo. Mechanistically, we demonstrated that the 3D environment drives the cells towards a general metabolic reprogramming involving protein, lipid, and energy metabolism (e.g., increased glycolysis dependency). This metabolic change sensitizes PDAC cells to the anti-proliferative effect of budesonide, which instead induces opposite changes (e.g., increased mitochondrial oxidative phosphorylation). Finally, we provide evidence that budesonide inhibits PDAC growth, at least in part, through the tumor suppressor CDKN1C/p57Kip2.
Collectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer. |
|---|---|
| AbstractList | Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PDAC and the glucocorticoid (GC) budesonide, a first-line therapy to treat asthma. We tested the effect of budesonide and the classical GCs on the morphology, proliferation, migration and invasiveness of patient-derived PDAC cells and pancreatic cancer cell lines, using 2D and 3D cultures in vitro. Furthermore, a xenograft model was used to investigate the effect of budesonide on PDAC tumor growth in vivo. Finally, we combined genome-wide transcriptome analysis with genetic and pharmacological approaches to explore the mechanisms underlying budesonide activities in the different environmental conditions. We found that in 2D culture settings, high micromolar concentrations of budesonide reduced the mesenchymal invasive/migrating features of PDAC cells, without affecting proliferation or survival. This activity was specific and independent of the Glucocorticoid Receptor (GR). Conversely, in a more physiological 3D environment, low nanomolar concentrations of budesonide strongly reduced PDAC cell proliferation in a GR-dependent manner. Accordingly, we found that budesonide reduced PDAC tumor growth in vivo. Mechanistically, we demonstrated that the 3D environment drives the cells towards a general metabolic reprogramming involving protein, lipid, and energy metabolism (e.g., increased glycolysis dependency). This metabolic change sensitizes PDAC cells to the anti-proliferative effect of budesonide, which instead induces opposite changes (e.g., increased mitochondrial oxidative phosphorylation). Finally, we provide evidence that budesonide inhibits PDAC growth, at least in part, through the tumor suppressor CDKN1C/p57Kip2. Collectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer. BackgroundPancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PDAC and the glucocorticoid (GC) budesonide, a first-line therapy to treat asthma.MethodsWe tested the effect of budesonide and the classical GCs on the morphology, proliferation, migration and invasiveness of patient-derived PDAC cells and pancreatic cancer cell lines, using 2D and 3D cultures in vitro. Furthermore, a xenograft model was used to investigate the effect of budesonide on PDAC tumor growth in vivo. Finally, we combined genome-wide transcriptome analysis with genetic and pharmacological approaches to explore the mechanisms underlying budesonide activities in the different environmental conditions.ResultsWe found that in 2D culture settings, high micromolar concentrations of budesonide reduced the mesenchymal invasive/migrating features of PDAC cells, without affecting proliferation or survival. This activity was specific and independent of the Glucocorticoid Receptor (GR). Conversely, in a more physiological 3D environment, low nanomolar concentrations of budesonide strongly reduced PDAC cell proliferation in a GR-dependent manner. Accordingly, we found that budesonide reduced PDAC tumor growth in vivo. Mechanistically, we demonstrated that the 3D environment drives the cells towards a general metabolic reprogramming involving protein, lipid, and energy metabolism (e.g., increased glycolysis dependency). This metabolic change sensitizes PDAC cells to the anti-proliferative effect of budesonide, which instead induces opposite changes (e.g., increased mitochondrial oxidative phosphorylation). Finally, we provide evidence that budesonide inhibits PDAC growth, at least in part, through the tumor suppressor CDKN1C/p57Kip2.ConclusionsCollectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer. Background Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PDAC and the glucocorticoid (GC) budesonide, a first-line therapy to treat asthma. Methods We tested the effect of budesonide and the classical GCs on the morphology, proliferation, migration and invasiveness of patient-derived PDAC cells and pancreatic cancer cell lines, using 2D and 3D cultures in vitro. Furthermore, a xenograft model was used to investigate the effect of budesonide on PDAC tumor growth in vivo. Finally, we combined genome-wide transcriptome analysis with genetic and pharmacological approaches to explore the mechanisms underlying budesonide activities in the different environmental conditions. Results We found that in 2D culture settings, high micromolar concentrations of budesonide reduced the mesenchymal invasive/migrating features of PDAC cells, without affecting proliferation or survival. This activity was specific and independent of the Glucocorticoid Receptor (GR). Conversely, in a more physiological 3D environment, low nanomolar concentrations of budesonide strongly reduced PDAC cell proliferation in a GR-dependent manner. Accordingly, we found that budesonide reduced PDAC tumor growth in vivo. Mechanistically, we demonstrated that the 3D environment drives the cells towards a general metabolic reprogramming involving protein, lipid, and energy metabolism (e.g., increased glycolysis dependency). This metabolic change sensitizes PDAC cells to the anti-proliferative effect of budesonide, which instead induces opposite changes (e.g., increased mitochondrial oxidative phosphorylation). Finally, we provide evidence that budesonide inhibits PDAC growth, at least in part, through the tumor suppressor CDKN1C/p57Kip2. Conclusions Collectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer. Keywords: Pancreatic cancer, 3D spheroids, Metabolic reprogramming, Cell proliferation, Budesonide, Glucocorticoids Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PDAC and the glucocorticoid (GC) budesonide, a first-line therapy to treat asthma.BACKGROUNDPancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PDAC and the glucocorticoid (GC) budesonide, a first-line therapy to treat asthma.We tested the effect of budesonide and the classical GCs on the morphology, proliferation, migration and invasiveness of patient-derived PDAC cells and pancreatic cancer cell lines, using 2D and 3D cultures in vitro. Furthermore, a xenograft model was used to investigate the effect of budesonide on PDAC tumor growth in vivo. Finally, we combined genome-wide transcriptome analysis with genetic and pharmacological approaches to explore the mechanisms underlying budesonide activities in the different environmental conditions.METHODSWe tested the effect of budesonide and the classical GCs on the morphology, proliferation, migration and invasiveness of patient-derived PDAC cells and pancreatic cancer cell lines, using 2D and 3D cultures in vitro. Furthermore, a xenograft model was used to investigate the effect of budesonide on PDAC tumor growth in vivo. Finally, we combined genome-wide transcriptome analysis with genetic and pharmacological approaches to explore the mechanisms underlying budesonide activities in the different environmental conditions.We found that in 2D culture settings, high micromolar concentrations of budesonide reduced the mesenchymal invasive/migrating features of PDAC cells, without affecting proliferation or survival. This activity was specific and independent of the Glucocorticoid Receptor (GR). Conversely, in a more physiological 3D environment, low nanomolar concentrations of budesonide strongly reduced PDAC cell proliferation in a GR-dependent manner. Accordingly, we found that budesonide reduced PDAC tumor growth in vivo. Mechanistically, we demonstrated that the 3D environment drives the cells towards a general metabolic reprogramming involving protein, lipid, and energy metabolism (e.g., increased glycolysis dependency). This metabolic change sensitizes PDAC cells to the anti-proliferative effect of budesonide, which instead induces opposite changes (e.g., increased mitochondrial oxidative phosphorylation). Finally, we provide evidence that budesonide inhibits PDAC growth, at least in part, through the tumor suppressor CDKN1C/p57Kip2.RESULTSWe found that in 2D culture settings, high micromolar concentrations of budesonide reduced the mesenchymal invasive/migrating features of PDAC cells, without affecting proliferation or survival. This activity was specific and independent of the Glucocorticoid Receptor (GR). Conversely, in a more physiological 3D environment, low nanomolar concentrations of budesonide strongly reduced PDAC cell proliferation in a GR-dependent manner. Accordingly, we found that budesonide reduced PDAC tumor growth in vivo. Mechanistically, we demonstrated that the 3D environment drives the cells towards a general metabolic reprogramming involving protein, lipid, and energy metabolism (e.g., increased glycolysis dependency). This metabolic change sensitizes PDAC cells to the anti-proliferative effect of budesonide, which instead induces opposite changes (e.g., increased mitochondrial oxidative phosphorylation). Finally, we provide evidence that budesonide inhibits PDAC growth, at least in part, through the tumor suppressor CDKN1C/p57Kip2.Collectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer.CONCLUSIONSCollectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer. Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PDAC and the glucocorticoid (GC) budesonide, a first-line therapy to treat asthma. Methods We tested the effect of budesonide and the classical GCs on the morphology, proliferation, migration and invasiveness of patient-derived PDAC cells and pancreatic cancer cell lines, using 2D and 3D cultures in vitro. Furthermore, a xenograft model was used to investigate the effect of budesonide on PDAC tumor growth in vivo. Finally, we combined genome-wide transcriptome analysis with genetic and pharmacological approaches to explore the mechanisms underlying budesonide activities in the different environmental conditions. Results We found that in 2D culture settings, high micromolar concentrations of budesonide reduced the mesenchymal invasive/migrating features of PDAC cells, without affecting proliferation or survival. This activity was specific and independent of the Glucocorticoid Receptor (GR). Conversely, in a more physiological 3D environment, low nanomolar concentrations of budesonide strongly reduced PDAC cell proliferation in a GR-dependent manner. Accordingly, we found that budesonide reduced PDAC tumor growth in vivo. Mechanistically, we demonstrated that the 3D environment drives the cells towards a general metabolic reprogramming involving protein, lipid, and energy metabolism (e.g., increased glycolysis dependency). This metabolic change sensitizes PDAC cells to the anti-proliferative effect of budesonide, which instead induces opposite changes (e.g., increased mitochondrial oxidative phosphorylation). Finally, we provide evidence that budesonide inhibits PDAC growth, at least in part, through the tumor suppressor CDKN1C/p57Kip2. Conclusions Collectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a lower occurrence of PDAC has been described in individuals with severe and long-standing asthma. Here we explored the potential link between PDAC and the glucocorticoid (GC) budesonide, a first-line therapy to treat asthma. We tested the effect of budesonide and the classical GCs on the morphology, proliferation, migration and invasiveness of patient-derived PDAC cells and pancreatic cancer cell lines, using 2D and 3D cultures in vitro. Furthermore, a xenograft model was used to investigate the effect of budesonide on PDAC tumor growth in vivo. Finally, we combined genome-wide transcriptome analysis with genetic and pharmacological approaches to explore the mechanisms underlying budesonide activities in the different environmental conditions. We found that in 2D culture settings, high micromolar concentrations of budesonide reduced the mesenchymal invasive/migrating features of PDAC cells, without affecting proliferation or survival. This activity was specific and independent of the Glucocorticoid Receptor (GR). Conversely, in a more physiological 3D environment, low nanomolar concentrations of budesonide strongly reduced PDAC cell proliferation in a GR-dependent manner. Accordingly, we found that budesonide reduced PDAC tumor growth in vivo. Mechanistically, we demonstrated that the 3D environment drives the cells towards a general metabolic reprogramming involving protein, lipid, and energy metabolism (e.g., increased glycolysis dependency). This metabolic change sensitizes PDAC cells to the anti-proliferative effect of budesonide, which instead induces opposite changes (e.g., increased mitochondrial oxidative phosphorylation). Finally, we provide evidence that budesonide inhibits PDAC growth, at least in part, through the tumor suppressor CDKN1C/p57Kip2. Collectively, our study reveals that the microenvironment influences the susceptibility of PDAC cells to GCs and provides unprecedented evidence for the anti-proliferative activity of budesonide on PDAC cells in 3D conditions, in vitro and in vivo. Our findings may explain, at least in part, the reason for the lower occurrence of pancreatic cancer in asthmatic patients and suggest a potential suitability of budesonide for clinical trials as a therapeutic approach to fight pancreatic cancer. |
| ArticleNumber | 165 |
| Audience | Academic |
| Author | Guardiola, Ombretta Altucci, Lucia De Cesare, Dario Andolfi, Gennaro Corona, Marco D’Aniello, Cristina Lonardo, Enza Sainz Jr, Bruno Saracino, Federica Colonna, Vincenza Ibello, Eduardo Amoroso, Filomena Cobellis, Gilda Minchiotti, Gabriella Buonaiuto, Silvia Patriarca, Eduardo Jorge Delle Cave, Donatella |
| Author_xml | – sequence: 1 givenname: Eduardo surname: Ibello fullname: Ibello, Eduardo – sequence: 2 givenname: Federica surname: Saracino fullname: Saracino, Federica – sequence: 3 givenname: Donatella surname: Delle Cave fullname: Delle Cave, Donatella – sequence: 4 givenname: Silvia surname: Buonaiuto fullname: Buonaiuto, Silvia – sequence: 5 givenname: Filomena surname: Amoroso fullname: Amoroso, Filomena – sequence: 6 givenname: Gennaro surname: Andolfi fullname: Andolfi, Gennaro – sequence: 7 givenname: Marco surname: Corona fullname: Corona, Marco – sequence: 8 givenname: Ombretta surname: Guardiola fullname: Guardiola, Ombretta – sequence: 9 givenname: Vincenza surname: Colonna fullname: Colonna, Vincenza – sequence: 10 givenname: Bruno surname: Sainz Jr fullname: Sainz Jr, Bruno – sequence: 11 givenname: Lucia surname: Altucci fullname: Altucci, Lucia – sequence: 12 givenname: Dario surname: De Cesare fullname: De Cesare, Dario – sequence: 13 givenname: Gilda surname: Cobellis fullname: Cobellis, Gilda – sequence: 14 givenname: Enza surname: Lonardo fullname: Lonardo, Enza – sequence: 15 givenname: Eduardo Jorge surname: Patriarca fullname: Patriarca, Eduardo Jorge – sequence: 16 givenname: Cristina surname: D’Aniello fullname: D’Aniello, Cristina – sequence: 17 givenname: Gabriella orcidid: 0000-0003-0225-9043 surname: Minchiotti fullname: Minchiotti, Gabriella |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38877560$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1rHCEUhoeS0ny0f6AXRSiU3kyq86HOVQmhH4FAb_ZeHD3OuszoVp3A5mf0F9fJpuluKMUL5fic93iO73lx4ryDonhL8CUhnH6KpMYNLXHVlLjGrCrJi-KMsJaWXUfpycH5tDiPcYMxJR3pXhWnNecs3-Gz4tdqHQBKbSdw0XonRwTuzgbvciChuESTvYeIttKpADJZhVQ-QkAKxjGi5FFaA5Iu2XIb_GgNhEzdAQJjQCXkDepnDdE7qwH1OxQgc0OQ02TdkMtBGHZogiT7nB2n18VLI8cIbx73i2L19cvq-nt5--PbzfXVbanark2lqvpKVnVfNaApoxK3usatIQy4wVRy1WhTUypbYKrvOol133GmWkaqnhFVXxQ3e1nt5UZsg51k2AkvrXgI-DAIGXK3I4i-banioE1Fmkbputes7jltaZPFJGVZ6_Neazv3E2iVRxfkeCR6fOPsWgz-ThBCGGvaLit8fFQI_ucMMYnJxmXA0oGfo6gx5fnHeEMy-v4ZuvFzyD-3UKyrWtJR_pcaZO7AOuNzYbWIiivWMc4qThbq8h9UXhomq7LdjM3xo4QPBwlrkGNaRz_OKXsnHoPvDkfyNIs_1stAtQdU8DEGME8IwWLxt9j7W2R_iwd_i6V3_ixJ2SSX4vnddvxf6m-7vQEA |
| CitedBy_id | crossref_primary_10_1016_j_biopha_2024_117750 crossref_primary_10_1021_acschembio_4c00870 |
| Cites_doi | 10.3390/pharmaceutics15071897 10.1677/jme.0.0300359 10.3332/ecancer.2015.597 10.3389/fphar.2018.00006 10.1007/s00280-014-2496-7 10.1371/journal.pone.0076518 10.1016/j.cmet.2015.08.015 10.1007/s11894-023-00863-y 10.1016/j.stemcr.2022.09.013 10.1016/j.ddtec.2017.03.002 10.1164/rccm.200608-1125OC 10.1158/1940-6207.CAPR-10-0182 10.1136/gutjnl-2015-310442 10.1038/s41388-020-1289-1 10.1530/ERC-20-0489 10.1200/JCO.2018.36.15_suppl.1568 10.1158/1078-0432.CCR-14-1051 10.1016/j.cell.2023.02.014 10.1186/s13046-023-02641-0 10.1016/j.stem.2011.10.001 10.1038/sj.neo.7900005 10.1158/1078-0432.CCR-04-2471 10.1158/0008-5472.CAN-14-0155 10.1038/ncomms14073 10.1158/0008-5472.CAN-23-2504 10.1006/jsre.1994.1105 10.1016/S0091-679X(10)96027-5 10.3390/ijms20184504 10.1186/s13046-020-01765-x 10.1038/s41598-020-66908-8 10.4161/cbt.7.7.6099 10.1038/s41467-021-24537-3 10.3389/fmolb.2020.00033 10.1158/0008-5472.CAN-18-2070 10.1007/s00535-013-0915-x 10.1186/s40170-022-00285-w 10.1007/978-1-4939-2895-8_5 10.1158/1078-0432.CCR-17-3070 10.1016/S0149-2918(02)80005-4 10.1016/j.celrep.2023.113612 10.1002/mc.22029 10.1097/ALN.0000000000000489 10.1245/s10434-018-6827-5 10.1038/ajg.2018.27 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13046-024-03072-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-9966 |
| EndPage | 20 |
| ExternalDocumentID | oai_doaj_org_article_b556c8edf2144cd3bd73b86564712a67 PMC11177459 A797872818 38877560 10_1186_s13046_024_03072_1 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: Ministero dell'Università e della Ricerca grantid: Young Researchers-MSCA-PNRR-MUR (MSCA_0000023) – fundername: Fondazione Umberto Veronesi grantid: Fondazione Umberto Veronesi – fundername: Fondazione Italiana per la ricerca sulle Malattie del Pancreas grantid: Fondazione Italiana per la ricerca sulle Malattie del Pancreas – fundername: Ministero dell'Università e della Ricerca grantid: PNRR project D3 4 Health (PNC 0000001) – fundername: Ministero dell'Università e della Ricerca grantid: PRIN 2022KME7RY – fundername: Associazione Italiana per la Ricerca sul Cancro grantid: IG 20736 – fundername: Associazione Italiana per la Ricerca sul Cancro grantid: Bridge Grant AIRC 2022 (#27012) |
| GroupedDBID | --- 0R~ 29K 2WC 4.4 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c595t-c2b2a23b24ed676a05d305f17e8f06a8c4df366a5e7cb99a0db987c5712b71c3 |
| IEDL.DBID | M48 |
| ISSN | 1756-9966 0392-9078 |
| IngestDate | Wed Aug 27 01:26:14 EDT 2025 Thu Aug 21 18:33:07 EDT 2025 Fri Jul 11 09:57:15 EDT 2025 Sat Jul 26 03:21:24 EDT 2025 Tue Jun 17 22:09:37 EDT 2025 Tue Jun 10 21:05:29 EDT 2025 Thu May 22 21:24:41 EDT 2025 Mon Jul 21 06:06:09 EDT 2025 Tue Jul 01 02:26:53 EDT 2025 Thu Apr 24 23:01:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cell proliferation Budesonide Metabolic reprogramming Glucocorticoids 3D spheroids Pancreatic cancer |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c595t-c2b2a23b24ed676a05d305f17e8f06a8c4df366a5e7cb99a0db987c5712b71c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-0225-9043 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13046-024-03072-1 |
| PMID | 38877560 |
| PQID | 3079251968 |
| PQPubID | 105475 |
| PageCount | 20 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b556c8edf2144cd3bd73b86564712a67 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11177459 proquest_miscellaneous_3068756841 proquest_journals_3079251968 gale_infotracmisc_A797872818 gale_infotracacademiconefile_A797872818 gale_healthsolutions_A797872818 pubmed_primary_38877560 crossref_primary_10_1186_s13046_024_03072_1 crossref_citationtrail_10_1186_s13046_024_03072_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-06-14 |
| PublicationDateYYYYMMDD | 2024-06-14 |
| PublicationDate_xml | – month: 06 year: 2024 text: 2024-06-14 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of experimental & clinical cancer research |
| PublicationTitleAlternate | J Exp Clin Cancer Res |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | I Mayayo-Peralta (3072_CR30) 2021; 28 P Gomez-Rubio (3072_CR4) 2017; 66 M Cavo (3072_CR20) 2020; 10 3072_CR13 3072_CR16 3072_CR15 G Sorrentino (3072_CR18) 2017; 8 J-H Egberts (3072_CR34) 2008; 7 S Sant (3072_CR24) 2017; 23 EJ O’Connell (3072_CR8) 2002; 24 G Veronesi (3072_CR44) 2011; 4 M Sandini (3072_CR32) 2018; 25 RF Willey (3072_CR6) 1982; 122 W Blaszczak (3072_CR36) 2024; 43 TM Ashton (3072_CR38) 2018; 24 3072_CR2 3072_CR3 S Hamada (3072_CR5) 2014; 49 C De Vitis (3072_CR35) 2023; 42 CJ Bruns (3072_CR17) 1999; 1 V Kumarasamy (3072_CR29) 2024; 84 K Alheim (3072_CR14) 2003; 30 SA Langhans (3072_CR19) 2018; 9 T Kuo (3072_CR21) 2015; 872 R Ellul-Micallef (3072_CR7) 1980; 61 MW Hess (3072_CR26) 2010; 96 L Cao (3072_CR37) 2020; 39 3072_CR28 J Norman (3072_CR33) 1994; 57 T Parimon (3072_CR45) 2007; 175 J Claytor (3072_CR9) 2023; 25 3072_CR43 N Sato (3072_CR42) 2005; 11 CJ Halbrook (3072_CR1) 2023; 186 TR Call (3072_CR31) 2015; 122 F Cermola (3072_CR11) 2022; 17 GR Lichtenstein (3072_CR10) 2018; 113 H Ishiguro (3072_CR23) 2014; 74 3072_CR40 S Prekovic (3072_CR41) 2021; 12 C Jensen (3072_CR25) 2020; 7 P Sancho (3072_CR39) 2015; 22 CJ Whatcott (3072_CR46) 2015; 21 F Amoroso (3072_CR12) 2023; 15 H Liang (3072_CR22) 2014; 53 TR Tidwell (3072_CR27) 2022; 10 |
| References_xml | – volume: 15 start-page: 1897 year: 2023 ident: 3072_CR12 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics15071897 – volume: 30 start-page: 359 year: 2003 ident: 3072_CR14 publication-title: J Mol Endocrinol doi: 10.1677/jme.0.0300359 – ident: 3072_CR43 doi: 10.3332/ecancer.2015.597 – volume: 9 start-page: 6 year: 2018 ident: 3072_CR19 publication-title: Front Pharmacol doi: 10.3389/fphar.2018.00006 – volume: 74 start-page: 249 year: 2014 ident: 3072_CR23 publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-014-2496-7 – ident: 3072_CR40 doi: 10.1371/journal.pone.0076518 – volume: 22 start-page: 590 year: 2015 ident: 3072_CR39 publication-title: Cell Metab doi: 10.1016/j.cmet.2015.08.015 – volume: 25 start-page: 45 year: 2023 ident: 3072_CR9 publication-title: Curr Gastroenterol Rep doi: 10.1007/s11894-023-00863-y – volume: 122 start-page: 138 year: 1982 ident: 3072_CR6 publication-title: Eur J Respir Dis Suppl – volume: 17 start-page: 2548 year: 2022 ident: 3072_CR11 publication-title: Stem Cell Rep doi: 10.1016/j.stemcr.2022.09.013 – volume: 23 start-page: 27 year: 2017 ident: 3072_CR24 publication-title: Drug Discov Today Technol doi: 10.1016/j.ddtec.2017.03.002 – volume: 175 start-page: 712 year: 2007 ident: 3072_CR45 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200608-1125OC – volume: 4 start-page: 34 year: 2011 ident: 3072_CR44 publication-title: Cancer Prev Res (Phila Pa) doi: 10.1158/1940-6207.CAPR-10-0182 – volume: 66 start-page: 314 year: 2017 ident: 3072_CR4 publication-title: Gut doi: 10.1136/gutjnl-2015-310442 – ident: 3072_CR15 doi: 10.1038/s41388-020-1289-1 – volume: 28 start-page: R157 year: 2021 ident: 3072_CR30 publication-title: Endocr Relat Cancer doi: 10.1530/ERC-20-0489 – ident: 3072_CR3 doi: 10.1200/JCO.2018.36.15_suppl.1568 – volume: 21 start-page: 3561 year: 2015 ident: 3072_CR46 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1051 – volume: 61 start-page: 167 year: 1980 ident: 3072_CR7 publication-title: Eur J Respir Dis – volume: 186 start-page: 1729 year: 2023 ident: 3072_CR1 publication-title: Cell doi: 10.1016/j.cell.2023.02.014 – volume: 42 start-page: 69 year: 2023 ident: 3072_CR35 publication-title: J Exp Clin Cancer Res CR doi: 10.1186/s13046-023-02641-0 – ident: 3072_CR16 doi: 10.1016/j.stem.2011.10.001 – volume: 1 start-page: 50 year: 1999 ident: 3072_CR17 publication-title: Neoplasia N Y N doi: 10.1038/sj.neo.7900005 – volume: 11 start-page: 4681 year: 2005 ident: 3072_CR42 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-2471 – ident: 3072_CR2 doi: 10.1158/0008-5472.CAN-14-0155 – volume: 8 start-page: 14073 year: 2017 ident: 3072_CR18 publication-title: Nat Commun doi: 10.1038/ncomms14073 – volume: 84 start-page: 1115 year: 2024 ident: 3072_CR29 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-23-2504 – volume: 57 start-page: 33 year: 1994 ident: 3072_CR33 publication-title: J Surg Res doi: 10.1006/jsre.1994.1105 – volume: 96 start-page: 649 year: 2010 ident: 3072_CR26 publication-title: Methods Cell Biol doi: 10.1016/S0091-679X(10)96027-5 – ident: 3072_CR28 doi: 10.3390/ijms20184504 – volume: 39 start-page: 267 year: 2020 ident: 3072_CR37 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-020-01765-x – volume: 10 start-page: 10192 year: 2020 ident: 3072_CR20 publication-title: Sci Rep doi: 10.1038/s41598-020-66908-8 – volume: 7 start-page: 1044 year: 2008 ident: 3072_CR34 publication-title: Cancer Biol Ther doi: 10.4161/cbt.7.7.6099 – volume: 12 start-page: 4360 year: 2021 ident: 3072_CR41 publication-title: Nat Commun doi: 10.1038/s41467-021-24537-3 – volume: 7 start-page: 33 year: 2020 ident: 3072_CR25 publication-title: Front Mol Biosci doi: 10.3389/fmolb.2020.00033 – ident: 3072_CR13 doi: 10.1158/0008-5472.CAN-18-2070 – volume: 49 start-page: 605 year: 2014 ident: 3072_CR5 publication-title: J Gastroenterol doi: 10.1007/s00535-013-0915-x – volume: 10 start-page: 9 year: 2022 ident: 3072_CR27 publication-title: Cancer Metab doi: 10.1186/s40170-022-00285-w – volume: 872 start-page: 99 year: 2015 ident: 3072_CR21 publication-title: Adv Exp Med Biol doi: 10.1007/978-1-4939-2895-8_5 – volume: 24 start-page: 2482 year: 2018 ident: 3072_CR38 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-3070 – volume: 24 start-page: 887 year: 2002 ident: 3072_CR8 publication-title: Clin Ther doi: 10.1016/S0149-2918(02)80005-4 – volume: 43 start-page: 113612 year: 2024 ident: 3072_CR36 publication-title: Cell Rep doi: 10.1016/j.celrep.2023.113612 – volume: 53 start-page: 753 year: 2014 ident: 3072_CR22 publication-title: Mol Carcinog doi: 10.1002/mc.22029 – volume: 122 start-page: 317 year: 2015 ident: 3072_CR31 publication-title: Anesthesiology doi: 10.1097/ALN.0000000000000489 – volume: 25 start-page: 4020 year: 2018 ident: 3072_CR32 publication-title: Ann Surg Oncol doi: 10.1245/s10434-018-6827-5 – volume: 113 start-page: 481 year: 2018 ident: 3072_CR10 publication-title: Am J Gastroenterol doi: 10.1038/ajg.2018.27 |
| SSID | ssj0061919 |
| Score | 2.3977904 |
| Snippet | Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis. Interestingly, a... Background Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis.... BackgroundPancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis.... Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer with an aggressive metastatic phenotype and very poor clinical prognosis.... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 165 |
| SubjectTerms | 3D spheroids Aggregates Analysis Animals Apoptosis Asthma Budesonide Budesonide - pharmacology Budesonide - therapeutic use Cancer therapies Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - pathology Cell growth Cell Line, Tumor Cell Movement - drug effects Cell proliferation Cell Proliferation - drug effects Corticosteroids Energy Metabolism - drug effects Ethylenediaminetetraacetic acid Flow cytometry Genomics Glucocorticoids Health aspects Humans Kinases Metabolic reprogramming Metabolism Metastasis Mice Microscopy Morphology Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Penicillin Photographic industry Prognosis Spheroids Stem cells Xenograft Model Antitumor Assays |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojxDCxgJiQOyGifxI8eCqCqkclqk3iy_IiJ1d6sme4CfwS9mxs5GGyHBhWtmbK1nxjPj9cxnQt4pCzGvdoKVtlKsUSIwW0nNdAwcXEPVtQEbnK--ystvzZdrcX3w1BfWhGV44Cy4MyeE9DCyQ2wvH2oXYGoNWQh41crK1EcOMW9_mMo-GE4FvN23yGh5NnC8AGQQjxgadcX4IgwltP4_ffJBUFoWTB5EoItH5OGUOtLz_JOPyb24eUzuX02X40_IrxXoJbKAeP0Za4MetLHRAb-O_c84UPAAOVn01KPW7yj-fz_QcUshH6Qg7J7d4nM-XczA4DSXfdBtR90uRMjR-xCp-0EREzMVeK0hBNKYGgnpOo5gWjf9sH5KVhefV58u2fTkAvOiFSPzlatsVbuqiUEqaUsRwCF0XEXdldJq34SultKKqLxrW1sG12rlBejCKe7rZ-Ros93EF4TWsfaQ-8BcVjZl4K2zHaRaMBHkMODUCsL3CjB-giPHVzFuTDqWaGmy0gwozSSlGV6QD_OY2wzG8Vfuj6jXmROBtNMHMC8zmZf5l3kV5A1ahcldqbM7MOcKjt8KobQK8j5xoEOABXg79TWAGBBaa8F5uuCEjeyX5L3lmcmRDAaW0mJzsQTy25mMI7E4bhO3O-SRcOqUuoElP8-GOi-6hiACtLIgemHCC6ksKZv-e4IZ53if34j25f-Q4wl5UKXtJxlvTsnReLeLryCdG93rtHN_A8UiSLY priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifl_11AiCDxKuSZukfZJTPA7hfFph30K-qgu323XbfdA_w7_YmbRbrwj32kxLk_llZvIxvyHkrbbg8wonWW6FZqWWgVmhKlbFwME0iKYOmOB8-VVdfCu_LOVy3HDrxmuVB5uYDHVoPe6RnwIWa8yyVNWH7U-GVaPwdHUsoXGb3EHqMkS1Xk4LLlgbpMIe4CEVw7j-kDRTqdOO45EgAw_FEOaC8ZljSvz9_1vpa25qfoXymk86f0Duj8EkPRu0_5DciptH5O7leFz-mPxZgKYiC8jgP7Bv0GuJbbTDp_3qd-wo2IQhfPTUIw52FHf0O9q3FCJECsO_Ylss8NPEgSqcDhdBaNtQtw8RovZViNT9osiSma58rcEp0phSC-k69gC2q1W3fkIW558Xny7YWISBeVnLnnnhhBWFE2UMSiubywAmouE6Vk2ubOXL0BRKWRm1d3Vt8-DqSnupuXCa--IpOdq0m3hMaBELD9EQfMuqMg-8draB4As-BFENmLmM8IMCjB8JyrFOxpVJC5VKmUFpBpRmktIMz8j76Z3tQM9xo_RH1OskidTa6UG7-27GmWqclMoDVBskk_OhcAGwXEHYC25cWKUz8hpRYYY81clAmDMNC3KN5FoZeZck0ERAB7wdMx1gGJBsayZ5MpOEqe3nzQfkmdG0dObfRMjIm6kZ38TrcpvY7lFGwTpUVSV0-dkA1KnTBbgVaMszUs0gPBuVectm9SMRj3M84S9l_fzm_3pB7ok0sRTj5Qk56nf7-BJCt969SvPzL8qCQnM priority: 102 providerName: ProQuest |
| Title | Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38877560 https://www.proquest.com/docview/3079251968 https://www.proquest.com/docview/3068756841 https://pubmed.ncbi.nlm.nih.gov/PMC11177459 https://doaj.org/article/b556c8edf2144cd3bd73b86564712a67 |
| Volume | 43 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1baxQxFA61BfFFvLu2rhEEHyQ61yTzINKVliJskbKFxZeQ2-jCXurOLLT-DH-x52Rmhx0s4ss8TM4EknOf5HyHkDdCg89LTc4inQiWidwxnXDJpHcxmIakLBwWOI_P-dll9mWaT_fItt1Ru4HVrakd9pO6XM_fX_-8-QQK_zEovOQfqhiP9xh4G4YimzDIhg7AMwnsaDDOulMFyBVCo48IYgIGSaHcFtHcOkfPUQU8_7-t9o7b6l-p3PFRpw_I_Ta4pMeNNDwke375iNwdt8fnj8nvCXDOM4eI_g0aB90pdKMVvq1nv3xFwUY04aSlFuViTfEPf0XrFYWIkQI7ZuwKG_6UvoEOp83FELoqqdk4D1H8zHlqbiiiZoYrYAtwktSHUkO68DUI33xWLZ6QyenJ5PMZa5syMJsXec1sYhKdpCbJvOOC6yh3YDLKWHhZRlxLm7ky5VznXlhTFDpyppDC5iJOjIht-pTsL1dL_5zQ1KcWoiOYS_MscnFhdAnBGEwEUQ6YvQGJtwxQtgUsx74ZcxUSF8lVwzQFTFOBaSoekHfdN1cNXMc_qUfI144SobbDi9X6u2o1V5k85xZEt0RwOetS40C2JYTB4NYTzcWAvEKpUE3damcw1LGABF0g2NaAvA0UKMSwAKvbygfYBgTf6lEe9ShB1W1_eCt5aqspCpZSYPkxh-HX3TB-idfnln61QRoOeSmXGSz5WSOo3aJTcDMwFg2I7Ilwb1f6I8vZjwBEHuOJf5YXL_57gYfkXhJ0jLM4OyL79XrjX0JUV5shuSOmYkgORifnXy-G4d_IMKgvPC9G3_4AuB1OKg |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkIAXxHUEBjMSiAdkLXESO3lAaFymjq17KlLfLMd2oNLalCYVGj-D_8F_5BwnDY2Q9rbX-MSqc75zq8-FkFdSg82Li5SFmkuWyNQyzUXGMmcjUA28zC0WOI_Pxehr8mWaTnfIn00tDKZVbnSiV9S2Mvgf-SFgMccqS5G9X_5gODUKb1c3IzRaWJy6y58QstXvTj4Bf19zfvx58nHEuqkCzKR52jDDC655XPDEWSGFDlMLmC8j6bIyFDoziS1jIXTqpCnyXIe2gLjcpDLihYxMDNveIDfB7oYY68lpH99BKOLniIBBFgzDiE2NTiYO6whvIBkYRIZSxVk0sIN-XMD_RmHLKg4zNrdM4PE9crfzXelRC7b7ZMctHpBb4-52_iH5PQFgOGZxYEDb7INu1dHRGp82s1-upqCCWm_VUIOwW1G8QKhpU1FwSClwe8aWOE-odG1nctrmndCqpMXaOggSZtbR4pJiU06fYTYHG0ydr2Skc9cAti9m9fwRmVwHdx6T3UW1cE8IjV1swPmCvbRIQhvlhS7B14ONwIkCrRqQaMMAZbp-6DiW40L5uCgTqmWaAqYpzzQVBeRt_86y7QZyJfUH5GtPiZ28_YNq9U11ikEVaSoMSEaJveuMjQsLopOBlw1eA9dCBuQAUaHastheH6kjCfG_xF5eAXnjKVAjwQGM7gor4DNgb68B5f6AEjSJGS5vkKc6TVarf3IXkJf9Mr6J2XkLV62RRkDYK7IEjrzXArU_dAxWDNbCgGQDCA--ynBlMfvu-5xHmFCQpPnTq3_XAbk9mozP1NnJ-ekzcod7IRMsSvbJbrNau-fgNTbFCy-rlKhr1g1_ATxOfww |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Three-dimensional+environment+sensitizes+pancreatic+cancer+cells+to+the+anti-proliferative+effect+of+budesonide+by+reprogramming+energy+metabolism&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Ibello%2C+Eduardo&rft.au=Saracino%2C+Federica&rft.au=Delle+Cave%2C+Donatella&rft.au=Buonaiuto%2C+Silvia&rft.date=2024-06-14&rft.pub=BioMed+Central+Ltd&rft.issn=0392-9078&rft.volume=43&rft.issue=1&rft_id=info:doi/10.1186%2Fs13046-024-03072-1&rft.externalDocID=A797872818 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |